Etid klinik pou Limfom nan Maryland
21 etid pou Limfom ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT03258567Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 3 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT01441089CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT00006518Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Sep 28, 2026 · NCT00923507Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT03223610Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Maryland Oncology Hematology, Silver Spring
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Ap rekriteFaz 1/2
12 Months – 21 Years · Tout sèks · Mizajou Sep 11, 2026 · NCT04870944Sample Collection and Tracking for the Developmental Therapeutics Clinic
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 8, 2026 · NCT03269578Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Bethesda
Ap rekriteFaz 3
Laj 18 a 18 · Tout sèks · Mizajou Sep 8, 2026 · NCT07509151Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 4 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07652580Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT05237986Vaccine Responses in Patients With B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 4
Laj 18 a 90 · Tout sèks · Mizajou Aug 4, 2026 · NCT05170399DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 1, 2026 · NCT05663502Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 120 · Tout sèks · Mizajou May 27, 2026 · NCT06856226Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.